Literature DB >> 27558181

Coinfection and Emergence of Rifamycin Resistance during a Recurrent Clostridium difficile Infection.

Emma C Stevenson1,2, Giles A Major3, Robin C Spiller3, Sarah A Kuehne1,2, Nigel P Minton4,2.   

Abstract

Clostridium difficile (Peptoclostridium difficile) is a common health care-associated infection with a disproportionately high incidence in elderly patients. Disease symptoms range from mild diarrhea to life-threatening pseudomembranous colitis. Around 20% of patients may suffer recurrent disease, which often requires rehospitalization of patients. C. difficile was isolated from stool samples from a patient with two recurrent C. difficile infections. PCR ribotyping, whole-genome sequencing, and phenotypic assays were used to characterize these isolates. Genotypic and phenotypic screening of C. difficile isolates revealed multiple PCR ribotypes present and the emergence of rifamycin resistance during the infection cycle. Understanding both the clinical and bacterial factors that contribute to the course of recurrent infection could inform strategies to reduce recurrence. (This study has been registered at ClinicalTrials.gov under registration no. NCT01670149.).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27558181      PMCID: PMC5078544          DOI: 10.1128/JCM.01025-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

2.  Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent Clostridium difficile infections.

Authors:  M Mac Aogáin; G Moloney; S Kilkenny; M Kelleher; M Kelleghan; B Boyle; T R Rogers
Journal:  J Hosp Infect       Date:  2015-02-26       Impact factor: 3.926

3.  Conserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile.

Authors:  Adrianne N Edwards; Kathryn L Nawrocki; Shonna M McBride
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

4.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

5.  High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Authors:  Scott R Curry; Jane W Marsh; Kathleen A Shutt; Carlene A Muto; Mary M O'Leary; Melissa I Saul; A William Pasculle; Lee H Harrison
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

6.  Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.

Authors:  Stuart Johnson; Christopher Schriever; Ursula Patel; Toral Patel; David W Hecht; Dale N Gerding
Journal:  Anaerobe       Date:  2009-08-18       Impact factor: 3.331

Review 7.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Authors:  Stuart Johnson
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

8.  Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes.

Authors:  Iñaki Comas; Sonia Borrell; Andreas Roetzer; Graham Rose; Bijaya Malla; Midori Kato-Maeda; James Galagan; Stefan Niemann; Sebastien Gagneux
Journal:  Nat Genet       Date:  2011-12-18       Impact factor: 38.330

Review 9.  Within-host evolution of bacterial pathogens.

Authors:  Xavier Didelot; A Sarah Walker; Tim E Peto; Derrick W Crook; Daniel J Wilson
Journal:  Nat Rev Microbiol       Date:  2016-01-19       Impact factor: 60.633

10.  Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.

Authors:  David W Eyre; Farah Babakhani; David Griffiths; Jaime Seddon; Carlos Del Ojo Elias; Sherwood L Gorbach; Tim E A Peto; Derrick W Crook; A Sarah Walker
Journal:  J Infect Dis       Date:  2013-11-11       Impact factor: 5.226

View more
  1 in total

1.  Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia.

Authors:  Marina Muñoz; Daniel Restrepo-Montoya; Nitin Kumar; Gregorio Iraola; Milena Camargo; Diana Díaz-Arévalo; Nelly S Roa-Molina; Mayra A Tellez; Giovanny Herrera; Dora I Ríos-Chaparro; Claudia Birchenall; Darío Pinilla; Juan M Pardo-Oviedo; Giovanni Rodríguez-Leguizamón; Diego F Josa; Trevor D Lawley; Manuel A Patarroyo; Juan David Ramírez
Journal:  Sci Rep       Date:  2019-08-05       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.